View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 17, 2020updated 12 Jul 2022 11:57am

UCL researchers test cough syrup drug for Parkinson’s

A research team at University College London has secured funding to evaluate the use of cough syrup drug ambroxol to treat Parkinson’s disease patients in clinical trials.

A research team at University College London has secured funding to evaluate the use of cough syrup drug ambroxol to treat Parkinson’s disease patients in clinical trials.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Ambroxol was originally intended to clear phlegm and ease coughing in patients with respiratory diseases.

In a recent study conducted by the university’s researchers, the drug was observed to be safe and well-tolerated in 17 Parkinson’s patients.

The drug was found to have effectively crossed the blood-brain barrier and elevated the glucocerebrosidase (GCase) protein levels in the brain cells of the subjects.

GCase protein enables the effective removal of waste by cells. This function is known to be deficient in some patients with Parkinson’s.

It is expected that increasing levels of the protein may help in keeping cells healthier for longer and, in turn, slow disease progression in this patient population. These study findings were published in the JAMA Neurology journal.

Based on the results, the Cure Parkinson’s Trust (CPT), the Van Andel Institute (VAI), and the John Black Charitable Foundation agreed to provide £522,126 in funding to advance the drug into further clinical trials.

A new trial at the Leonard Wolfson Experimental Neurology Centre at UCL will aim to determine the optimal ambroxol dosage. This study is expected to begin this year and will be followed by a larger trial.

UCL Queen Square Institute of Neurology professor Tony Schapira said: “By increasing levels of GCase, ambroxol allows cells to remove waste, which would ideally keep cells healthier for longer and could slow down the progression of Parkinson’s.”

CPT CEO Will Cook said: “This will enable the launch of many more clinical trials of potentially disease-modifying repurposed and novel drugs that have been identified through the diligent iLCT process, and thereby bringing us closer to our goal, a cure for the ten million people living with Parkinson’s globally.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena